Faculty Presentations

Saturday, Oct. 22

Master Class 01 | Radiopharmaceutical Therapy Master Class
Lu-177-PSMA (Prostate) & Lu-177-Dotatate (NET)
1 p.m.
Room 302

PRESENTERS:
Hyun Kim, MD – Moderator and Presenter
Jeff Michalski, MD, MBA, FASTRO
Jacqueline Zoberi, PhD
Nikki Maughan, PhD, MS

Sunday, Oct. 23

PS 02 | Presidential Symposium: Session II — Prevention and Mitigation of Radiation Toxicity
Normal Tissue Injury, Specifically in the Cardiovascular System
1 p.m.
Stars at Night Ballroom
PRESENTER: Carmen Bergom, MD, PhD

EDU 04 | State of the ART: Clinical, Technical and Practical Considerations in Adaptive Radiation
Clinical Considerations for Adaptive Radiotherapy
4:45 p.m.
Room 006
PRESENTER: Lauren Henke, MD, MS

Panel 04 | Manipulating Metabolism to Enhance Radiation Therapy
Glucose, Glutamine Metabolism and Radiation-Sensitization in Cervical Cancer
4:45 p.m.
Room 214
PRESENTER: Julie Schwarz, MD, PhD

Monday, Oct. 24

EDU 06 | (Live SA-CME) Rectal Cancer Nonoperative Management: Tools for the Clinician to Enable Patient-Centered Decisions
Gastrointestinal Cancer Track
8 a.m.
Room 006
MODERATOR AND PRESENTER: Hyun Kim, MD

EDU 07 | All About Dose: From 400cGy to 5000cGy — What Influences Dose and Schedule Across the Spectrum of Lymphomas?
Hematologic Malignancies
8 a.m.
Room 206
MODERATOR: Joanna Yang, MD, MPH

Tuesday, Oct. 25

EDU 14 | (Live SA-CME) Managing Challenging Cases: Bladder Cancer
Challenging Cases for Bladder Cancer: Treatment Planning and Technique Genitourinary Cancer
8 a.m.
Room 217
MODERATOR AND PRESENTER: Brian Baumann, MD

QP 13 | H&N 2 – New Directions for HPV Associated (and HPV Negative) SCCA
1078 – Quantification of Tumor-Associated Cell-Free HPV DNA in Surgical Drain Fluid Equates to Molecular Residual Disease and Correlates with High-Risk Pathology
2:30 p.m.
Room 304
PRESENTER: Noah Earland, BS

SS 21 | Bio 5 – Normal Tissue Injury and Dose Rate Effects
Radiation and Cancer Biology
2:30 p.m.
Room 206
MODERATOR: Carmen Bergom, MD, PhD

Panel 20 | Emerging Concepts and Therapeutic Opportunities in Late Toxicity of Normal Tissues
Advances in Radiation-Induced Cardiac Toxicity
4 p.m.
Room 007 A/B
PRESENTER: Carmen Bergom, MD, PhD

SS 25 | GU 5 – Bladder and Kidney Preservation
Genitourinary Cancer
5:15 p.m.
Hemisfair Ballroom C1
MODERATOR : Brian Baumann, MD

Wednesday, Oct. 26

EDU 30 | Non-Invasive Ablation of Ventricular Tachycardia: Experiences and Challenges From Emerging Preclinical and Clinical Studies in Photon and Particle Therapy
Radiation Oncologist Perspective: Clinical Workflow for VT Ablation
8 a.m.
Room 206
MODERATOR AND PRESENTER: Cliff Robinson, MD

Photon Ablation of VT: Challenges and Solutions in Physics Workflow
8 a.m.
Room 206
MODERATOR AND PRESENTER: Geoffrey Hugo, PhD

Panel 23 | Deciding Between Nothing and Everything: Boost, Bolus and Fraction Numbers in Breast Radiotherapy
Breast Cancer
8 a.m.
Room 217
MODERATOR AND PRESENTER: Carmen Bergom, MD, PhD

CB 01 | Cancer Breakthroughs
Special Session
9:15 a.m.
Stars at Night Ballroom
MODERATOR: Jeff Michalski, MD, MBA, FASTRO

SS 30 | GYN 2 – Personalized Care and Novel Advances in Gynecological Cancers
264 – Exploiting Pretreatment Nodal Involvement to Identify Drivers of Chemoradiation Resistance in Locally Advanced Cervical Cancer
11 a.m.
Room 206
PRESENTER: Michael Waters, MD, PhD

EDU 33 | CAR T-Cell Therapy and Radiation Therapy for Hematologic Malignancies: Translating Science from the Lab to the Clinic
RT and Cellular Therapy: Mechanisms Underlying Synergistic Combined Modality Strategies
12:30 p.m.
Room 302
PRESENTER: Carl DeSelm, MD, PhD

SS 34 | HSR 2 – Radiation Oncology Payment Policy and Economics
291 – The Impact of Federal Poverty Level on the Association between Insurance Status and Overall Survival among Adults with Cancer
1:30 p.m.
Room 206
PRESENTER: Justin Barnes, MD, MS

Poster Q&A Sessions (Henry B. Gonzalez Convention Center | Exhibit Hall 1)

Q&A 01 | Lung Cancer and DEIH
Sunday, Oct. 23, 4:45 p.m.

2291 – Disparities in Specialized Radiation Treatment Modalities for Grade Group 2, Intermediate-Risk Prostate Cancer
PRESENTER: Ben Fischer-Valuck, MD

Q&A 02 | Central Nervous System and Palliative Care
Monday, Oct 24, 10:45 a.m.

2152 – A Propensity-Matched Study to Evaluate PTEN and TP53 Mutations as Predictive Biomarkers of Survival in Newly Diagnosed IDH-Wildtype Glioblastoma after Tumor Treating Fields
PRESENTER: James Cordova, MD, PhD

Q&A 03 | Breast Cancer and Nonmalignant Disease
Monday, Oct. 24, 3 p.m.

2027 – Cardiotoxicity in Patients with Ductal Carcinoma In Situ (DCIS) in the Contemporary Radiotherapy Era
2080 – Cardiac Events in Breast Cancer Patients Treated With Modern Radiotherapy
PRESENTER: Maria A. Thomas, MD, PhD

Q&A 04 | Biology and PRO
Monday, Oct. 24, 5 p.m.

3188 – avb6 Integrin-Targeted PET Imaging to Monitor Radiation-Induced Pulmonary Fibrosis In Vivo
PRESENTER: William Lo, MD, PhD

Q&A 05 | Gastrointestinal Cancer and Sarcoma
Tuesday, Oct. 25, 12:45 p.m.

2434 – Surface Imaging-Guided Adaptive Radiotherapy (ART): Imaging Protocol and Verification for Inter- and Intra- Fractional Motion Managements
PRESENTER: Alex Price, MS

2419 – In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Abdominal Oligometastases
PRESENTER: Hayley Stowe, MD

2337 – Convolutional Neural Network Classification of Pretreatment Biopsies of Rectal Adenocarcinoma Predicts Complete Clinical Response to Short-Course Radiation and Consolidation Chemotherapy
PRESENTER: Michael Waters, MD, PhD

Q&A 06 | Genitourinary Cancer, Patient Safety, and Nursing
Tuesday, Oct. 25, 2:30 p.m.

2452 – Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
PRESENTER: Neal Andruska, MD, PhD

2459 – CT-Guided Adaptive Radiotherapy (CT-ART) Improves Target Coverage in Hypofractionated Radiation Therapy for Bladder Cancer
PRESENTER: Hayley Stowe, MD

Q&A 07 | Hematologic Malignancies and Digital Health Innovation
Tuesday, Oct. 25, 4 p.m.

2795 – Incidence of Radiation Pneumonitis after a Single 550 cGy Fraction of Total Body Irradiation: Single Institutional Experience
PRESENTER: William Lo, MD, PhD

Q&A 08 | Gynecological Cancer, Pediatric Cancer, and Professional Development
Tuesday, Oct. 25, 5:15 p.m.

3067 – Dosimetric Predictors of Acute Lymphopenia during Proton Craniospinal Irradiation in Children
PRESENTER: James Cordova, MD, PhD

2565 – Development of a Radiomic Signature Derived from Apparent Diffusion Coefficient Maps to Predict Outcomes in Cervical Cancer
PRESENTER: LeMoyne Habimana-Griffin, MD, PhD

2622 – The Impact of Tumor Size and Histology on Local Control when Utilizing High-Dose-Rate Interstitial Brachytherapy for Gynecologic Malignancies
PRESENTER: Joshua Schiff, MD

Q&A 09 | Head & Neck Cancer and Health Services Research
Wednesday, Oct. 26, 10:30 a.m.

2748 – Cancer Mortality and the 2014 Medicaid Expansions Under the Affordable Care Act
PRESENTER: Justin Barnes, MD, MS

Q&A 10 | Physics
Wednesday, Oct. 26, 12:30 p.m.

3197 – In-Silico Trial of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRIBased and Online Adaptive Planning
PRESENTER: Kylie Kang, MD

3277 – A Prospective Feasibility Study Evaluating Skin Surface-Guided Gating as a Method to Manage Intrafraction Motion for Stereotactic Body Radiotherapy on a Novel Ring Gantry Machine
PRESENTER: Kendall Kiser, MD, MS

3203 – Optimizing the Small Animal Radiation Research Platform (SARRP) for High-Dose Rate Focal Irradiation Studies
PRESENTER: William Lo, MD, PhD

3340 – Adaptive Workflow for Whole Bladder Radiation Therapy with Simultaneous Integrated Boost on a CBCT Adaptive AI-Driven System
PRESENTER: Alex Price, MS

3319 – CT-Based Online Adaptive Prostate SBRT Improves Target Coverage and Reduces Rectal Dose
PRESENTER: Michael Waters, MD, PhD